Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Jul-Aug;17(4):396-402.
doi: 10.1136/jamia.2009.000992.

Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation

Esther S Park  1 , Marie R Peccoud, Kay A Wicks, Jeffrey B Halldorson, Robert L Carithers Jr, Jorge D Reyes, James D Perkins
Affiliations

Use of an automated clinical management system improves outpatient immunosuppressive care following liver transplantation

Esther S Park et al. J Am Med Inform Assoc. 2010 Jul-Aug.

Abstract

Objective: Immunosuppressive therapy following transplantation, if not managed well, can lead to increased drug toxicity or rejection episodes. We investigated whether use of an automated clinical management system in our liver transplant program would improve clinical outcomes in managing transplant recipients' immunosuppressive medications.

Design: We performed a retrospective cohort study of two patient groups receiving liver transplants at our institution. One group of 301 patients transplanted from January 1, 2004 to November 30, 2006 received outpatient immunosuppressive management using a paper charting system. After instituting an automated clinical management system, the following group of 127 patients transplanted from December 12, 2006 to April 1, 2008 received their outpatient immunosuppressive management with that system. Only patients who received tacrolimus therapy, with or without mycophenolate mofetil or prednisone, were studied.

Measurements: Our endpoints included percentage of patients having rejection and/or tacrolimus toxicity episodes. Various recipient, intraoperative, donor, and postoperative variables, including managing the immunosuppressive therapy with a paper charting system or an automated management system, were studied to determine which factors were associated with our endpoints.

Results: Multivariable logistic regression analysis showed the automated system was significantly associated with fewer rejection episodes and fewer tacrolimus toxicity events. Formal cost-effectiveness analysis of the nurses' salaries for 1 year showed the automated system cost US$197 per patient and the paper system cost US$1703 per patient. The automated system improved quality of life years.

Conclusion: Use of an automated clinical management system for outpatient immunosuppressive management for liver transplant patients has resulted in a decrease in both tacrolimus toxicity and rejection episodes and is cost-effective.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None.

Figures

Figure 1
Figure 1
In a sensitivity analysis evaluating the net health benefit on willingness to pay (US$1000 to $150 000), the paper charting system never became comparable to the automated clinical management system.
See this image and copyright information in PMC

References

    1. Perkins JD, Levy AE, Duncan JB, et al. Using root cause analysis to improve survival in a liver transplant population. J Surg Res 2005;129:6–16 - PubMed
    1. Moench C, Barreiros AP, Schuchmann M, et al. Tacrolimus monotherapy without steroids after liver transplantation – a prospective randomized double-blinded placebo-controlled trial. Am J Transplant 2007;7:1616–23 - PubMed
    1. Lerut J, Mathys J, Verbaandert C, et al. Tacrolimus monotherapy in liver transplantation: one-year results of a prospective, randomized, double-blind, placebo-controlled study. Ann Surg 2008;248:956–67 - PubMed
    1. Soliman T, Hetz H, Burghuber C, et al. Short-term versus long-term induction therapy with antithymocyte globulin in orthotopic liver transplantation. Transpl Int 2007;20:447–52 - PubMed
    1. Becker T, Foltys D, Bilbao I, et al. Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation 2008;86:1689–94 - PubMed

MeSH terms